ALL: Combining paediatric-type therapy with minimal residual disease
5 Dec 2016
ALL: Combining paediatric-type therapy with minimal residual disease
Advances in CLL from ASH 2016
Intravenous or subcutaenous rituximab for FL in the SABRINA study
Ibrutinib in CLL: RESONATE and resistance
Updates from the EURO-SKI trial of tyrosine kinase cessation
Novel antibody boosts responses in newly diagnosed AML
A new spin on leukaemia therapy
CPX-351 after stem cell transplant for elderly patients with AML
Managing breast cancer in low and middle income countries
Overall survival in older patients with glioblastoma
Abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
GI and gynaecological tumours in the elderly